Expert Ratings for Verve Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on Verve Therapeutics (NASDAQ:VERV) stock. The company has an average price target of $34.25, representing a 38.84% decrease from the previous average price target of $56.00. Two analysts have given bullish ratings, while two remained indifferent.
August 29, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Verve Therapeutics has received mixed reviews from analysts, with an average price target of $34.25, a significant decrease from the previous target.
The decrease in the average price target suggests that analysts have lowered their expectations for the stock, which could negatively impact its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100